Stocks › X › XNCR

Xencor, Inc. (XNCR) — Earnings Call X-Ray

Our AI read all 33 of XNCR's earnings calls (2016–2024) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q4 2023 · sign up to see
Previous Call Grade
C
Q3 2023
Expected Move
🔒
next 45 days · members
Calls Analyzed
33
2016–2024
Avg Candor
6.6/9
evasion 3.9/9
High CandorCritic AmmunitionFounder-LedQuestion Left Hanging

Call-by-call analysis

🔒 Q4 2023 earnings call 2024-02-28 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor ■/9
Specificity ■/9
Evasion ■/9
Stress ■/9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q4 2023 call grade is ready
The full 37-point AI read of XNCR's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

C Q3 2023 earnings call 2023-11-08

Management gave no formal guidance. The delivery was unusually candid.

10 analysts · 14 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubtsFounder-led
Candor 7/9
Specificity 6/9
Evasion 3/9
Confidence 6/9
Uncertainty 4/9
Promotion 5/9
Stress 2/9
Complexity 8/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

D Q2 2023 earnings call 2023-08-06

Management gave no formal guidance against steady demand.

Demand: stablePricing: stable 11 analysts · 20 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritableFounder-led
Candor 6/9
Specificity 6/9
Evasion 4/9
Confidence 7/9
Uncertainty 5/9
Promotion 5/9
Stress 2/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

F Q1 2023 earnings call 2023-05-08

Management gave no formal guidance.

Headcount: growing 13 analysts · 17 questions
⚑ Critic ammunition⚑ Question left hangingFounder-led
Candor 6/9
Specificity 4/9
Evasion 5/9
Confidence 7/9
Uncertainty 5/9
Promotion 6/9
Stress 3/9
Complexity 8/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

D Q4 2022 earnings call 2023-02-23

Management held guidance steady against steady demand. The delivery was unusually candid.

Guidance: maintainedDemand: stablePricing: stableHeadcount: growingCapex: increasing 12 analysts · 21 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritableFounder-led
Candor 7/9
Specificity 6/9
Evasion 5/9
Confidence 6/9
Uncertainty 6/9
Promotion 4/9
Stress 2/9
Complexity 8/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

C+ Q3 2022 earnings call 2022-11-07

Management lowered guidance. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: lowered 12 analysts · 26 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubtsFounder-led
Candor 7/9
Specificity 8/9
Evasion 3/9
Confidence 7/9
Uncertainty 4/9
Promotion 6/9
Stress 1/9
Complexity 7/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

B Q2 2022 earnings call 2022-08-03

Management raised guidance against steady demand. The delivery was unusually candid, relaxed under questioning.

Guidance: raisedDemand: stablePricing: stable 10 analysts · 18 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubtsFounder-led
Candor 7/9
Specificity 6/9
Evasion 3/9
Confidence 7/9
Uncertainty 4/9
Promotion 4/9
Stress 1/9
Complexity 8/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

C Q1 2022 earnings call 2022-05-08

Management held guidance steady against mixed demand signals. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: mixed 10 analysts · 17 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritableFounder-led
Candor 8/9
Specificity 7/9
Evasion 3/9
Confidence 6/9
Uncertainty 5/9
Promotion 4/9
Stress 2/9
Complexity 8/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

Earlier calls

CallDateGradeGuidanceDemandMarginsCandorEvasion
Q4 2021 2022-02-23 D maintainedunclearunclear 7/9 5/9
Q3 2021 2021-11-08 D maintainedstableunclear 7/9 4/9
Q2 2021 2021-08-05 D maintainedstableunclear 6/9 3/9
Q1 2021 2021-05-08 D maintainedstableunclear 7/9 4/9
Q4 2020 2021-02-24 C maintainedstablecontracting 7/9 4/9
Q3 2020 2020-11-08 D maintainedstablecontracting 7/9 6/9
Q2 2020 2020-08-05 C maintainedunclearcontracting 7/9 4/9
Q1 2020 2020-05-09 D maintainedstableunclear 7/9 4/9
Q4 2019 2020-02-24 D maintainedstableunclear 6/9 5/9
Q3 2019 2019-11-05 D maintainedstableunclear 6/9 5/9
Q2 2019 2019-08-06 D raisedstableunclear 6/9 4/9
Q1 2019 2019-05-10 C maintainedstableunclear 7/9 4/9
Q4 2018 2019-02-25 D maintainedunclearcontracting 7/9 5/9
Q3 2018 2018-11-05 D maintainedunclearunclear 7/9 4/9
Q2 2018 2018-08-06 D noneunclearcontracting 6/9 4/9
Q1 2018 2018-05-07 D noneunclearcontracting 6/9 2/9
Q4 2017 2018-02-27 C noneunclearcontracting 6/9 4/9
Q3 2017 2017-11-07 C noneunclearcontracting 7/9 3/9
Q2 2017 2017-08-07 D noneunclearcontracting 6/9 4/9
Q1 2017 2017-05-09 C raisedstablecontracting 6/9 5/9
Q4 2016 2017-02-28 B noneunclearcontracting 7/9 2/9
Q3 2016 2016-11-02 D noneunclearunclear 6/9 3/9
Q2 2016 2016-08-02 B+ nonestableunclear 7/9 3/9
Q1 2016 2016-05-02 D maintainedunclearunclear 5/9 4/9
Q4 2015 2016-03-09 C+ maintainedstableunclear 7/9 3/9

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AAP · Advance Auto Parts, Inc.ABCAF · Athabasca Minerals, Inc.ABDC · Alcentra Capital'sABMD · Abiomed, Inc.ABNRY · ABN AMRO Bank N.V.ABOS · Acumen Pharmaceuticals,

← XMTR   All “X” companies    XNET →

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.